Research Summary
Dr. Everett has become the program leader at Johns Hopkins in pediatric biomarker discovery, with a focus on neonatal brain injury and pulmonary hypertension. This includes both protein and metabolic indicators of diagnosis and outcomes.
He is the principal investigator (PI) or co-PI on multiple NIH- funded R01 studies. Active studies as PI include: NICHD R01 HD086058, "Adult Biomarkers in Neonatal Brain Injury and Development", NHLBI R01HL150070, "Role of IGF axis in pulmonary hypertension" and Children's Heart Foundation "Role of cyclohexanone toxicity in mediating congenital cardiac surgical outcomes". Co-investigator on NINDS R01 NS106292 "Biomarkers of Brain Injury in Critically-Ill Children on Extracorporeal Membrane Oxygenation (ECMO)", NINDS 1 U01 NS114144 "Blood test to aid treatment decisions for perinatal asphyxiation", NICHD 1R01HD100540 "Renal Anhydramnios Fetal Therapy (RAFT) Trial", NHLBI "The Hemodynamic and Metabolic Effects of Advanced Circulatory Support for Resuscitation" and NHLBI "IKDR-PREVAIL".
Technology Expertise Keywords
Proteomics; biomarkers; assay development; metabolomics
Selected Publications
View all on PubMed
Griffiths M, Yang J, Simpson CE, Vaidya D, Nies M, Brandal S, Damico R, Ivy D, Austin ED, Pauciulo MW, Lutz KA, Rosenzweig EB, Hirsch R, Yung D, Nichols WC, Everett AD. ST2 Is a Biomarker of Pediatric Pulmonary Arterial Hypertension Severity and Clinical Worsening. Chest. 2021 Feb 18:S0012-3692(21)00284-1. doi: 10.1016/j.chest.2021.01.085. Online ahead of print.
Yang J, Griffiths M, Nies MK, Brandal S, Damico R, Vaidya D, Tao X, Simpson CE, Kolb TM, Mathai SC, Pauciulo MW, Nichols WC, Ivy DD, Austin ED, Hassoun PM, Everett AD. Insulin-like growth factor binding protein-2: a new circulating indicator of pulmonary arterial hypertension severity and survival. BMC Med. 2020 Oct 6;18(1):268.
Griffiths M, Yang J, Nies M, Vaidya D, Brandal S, Williams M, Matsui EC, Grant T, Damico R, Ivy D, Austin ED, Nichols WC, Pauciulo MW, Lutz K, Rosenzweig EB, Hirsch R, Yung D, Everett AD.Pediatric pulmonary hypertension: insulin-like growth factor-binding protein 2 is a novel marker associated with disease severity and survival. Pediatr Res. 2020 Dec;88(6):850-856.
Dietrick B, Molloy E, Massaro AN, Strickland T, Zhu J, Slevin M, Donoghue V, Sweetman D, Kelly L, O'Dea M, McGowan M, Vezina G, Glass P, Vaidya D, Brooks S, Northington F, Everett AD. Plasma and CSF Candidate Biomarkers of Neonatal Encephalopathy Severity and Neurodevelopmental Outcomes. J Pediatr. 2020 Jun 28:S0022-3476(20)30832-5.
Chen JY, Griffiths M, Yang J, Nies MK, Damico RL, Simpson CE, Vaidya RD, Brandal S, Ivy DD, Austin ED, Nichols WC, Pauciulo MW, Lutz K, Rosenzweig EB, Hirsch R, Yung D, Everett AD. Elevated Interleukin-6 Levels Predict Clinical Worsening in Pediatric Pulmonary Arterial Hypertension. J Pediatr. 2020 Aug;223:164-169.
Patents
A Multi-protein Biomarker Assay for Brain Injury Detection and Outcome
Patent # WO2015009907 A1 | 01/22/2015
The present invention relates to the field of brain injuries. More specifically, the present invention provides methods and compositions useful in the diagnosis/prognosis/assessment of brain injuries. In a specific embodiment, a method for identifying which patients with traumatic brain injury (TBI) require a head computerized tomography (CT) scan for diagnosing acute intracranial pathology comprises the steps of (a) obtaining or collecting a sample from the patient; (b) measuring the levels of one or more biomarkers in the blood sample obtained from the patient, wherein the biomarkers comprise glial fibrillary acidic protein (GFAP), S100B, metallothionein 3 (MT3), neuron specific enolase (NSE) and intracellular adhesion molecule 5 (ICAM5); and (c) identifying the patient as requiring or not requiring a head CT scan based on the measured levels of one or more of biomarkers comprising GFAP, S100B, MT3, NSE and ICAM5.
Biosensor Systems and Related Methods for Detecting Analytes in Aqueous and Biological Environments
Patent # US20140349005 A1 | 11/27/2014
Disclosed herein are biosensor systems and related methods for detecting analytes in aqueous and biologic environments. A biosensor system for detecting binding of an analyte of interest may include a detector configured to detect a change in an electrical property on a surface thereof. The detector may be a FET. The system also may include a passive layer disposed on a top surface of the detector. Further, the system may include a hydrophobic layer disposed on the passive layer. The system also may include a receptor-attachment material configured for binding to an analyte. A receptor may bind to the analyte, and the receptor may be attached to the receptor-attachment material. The binding of the analyte to the receptor can cause the change of the electrical property at the surface. In response to the change for example, a current may change for indicating the binding of the analyte to the receptor.
Assay Reagents for a Neurogranin Diagnostic Kit
Patent # US20140141458 A1 | 05/22/2014
The present invention relates to the field of biomarkers. More specifically, the present invention relates to assay reagents useful in detecting neurogranin. In a specific embodiment, the present invention provides an isolated antibody or fragment thereof that specifically binds to neurogranin. In another embodiment, the present invention provides a polynucleotide aptamer that specifically binds neurogranin.
Assay Reagents for a Neurogranin Diagnostic Kit
Patent # EP2707389 A2 | 03/19/2014
The present invention relates to the field of biomarkers. More specifically, the present invention relates to assay reagents useful in detecting neurogranin. In a specific embodiment, the present invention provides an isolated antibody or fragment thereof that specifically binds to neurogranin. In another embodiment, the present invention provides a polynucleotide aptamer that specifically binds neurogranin.
Biomarkers of Pulmonary Hypertension
Patent # WO2013090811 A1 | 06/20/2013
Methods are disclosed for predicting or diagnosing pulmonary artery hypertension (PAH) and for determining the efficacy of PAH therapy using biomarkers.
